HONG KONG, January 9, 2026 /PRNewswire/ — Ribo Life Science Co., Ltd. (“Ribo” or the “Company”, stock code: 06938.HK), a leading company in the field of small interfering RNA (siRNA) therapeutics, is today successfully listed on the Main Board of the Hong Kong Stock Exchange, marking an important milestone in the capitalization of Chinese biopharmaceutical companies in the field of siRNA and injecting new impetus into the industry.
As part of its global offering, Ribo issued a total of 31,610,400 shares at an offering price of HK$57.97 per share, generating gross proceeds of over HK$1.8 billion, HKPO was over 100 times oversubscribed, International Placement was 16.7 times oversubscribed, reflecting global investors’ strong confidence in the value of the siRNA sector and the capabilities of the company. Proceeds from the IPO will provide strong financial support for the advancement of the Company’s core businesses. In addition, the offering attracted 12 key investors, including Arc Avenue, Ivy Rock, Springs Capital, China Asset Management, Dacheng International and Dacheng Fund, Taikang Life Insurance, etc., demonstrating the high confidence of major institutions in the long-term prospects of the Company.
Dr. Zicai Liang, Founder, Chairman and Managing Director of Ribo, commented: “Listing on the Hong Kong Stock Exchange represents a major milestone in Ribo’s journey. We express our sincere gratitude to global investors for their trust and support. Going forward, we will leverage international capital markets to accelerate the global clinical development and commercialization of siRNA therapies, further strengthen our technologies, bring breakthrough therapies to patients around the world while creating lasting value for shareholders.
Proceeds from the offering will be distributed across four key areas: (1) Advancing global multicenter clinical trials for core products; (2) Support the preclinical and clinical development of the pipeline; (3) Iteration and upgrade of siRNA delivery and other technology platforms; (4) Replenish operational capital and reserve funds for current business needs.
Ribo has built a fully integrated R&D platform with independent intellectual property rights. Its innovative RiboGalSTAR targeting the liverTM Delivery technology has successfully advanced several products to Phase II clinical trials. The Company has established R&D centers in Suzhou, Beijing and Gothenburg, Sweden, as well as a global R&D network capable of supporting end-to-end drug development, from discovery to global clinical trials.
The listing was jointly sponsored by China International Capital Corporation and Citigroup, which provided professional support for the company’s successful entry into the capital markets.
About Ribo Life Science
Suzhou Ribo Life Science Co., Ltd. (06938.HK) is a global biopharmaceutical company engaged in the development and commercialization of small interfering RNA (siRNA) therapeutics. Through its proprietary and innovative siRNA technology platforms, the company has built a rich and differentiated portfolio targeting major disease areas, including cardiovascular, metabolic, hepatic and renal diseases. Ribo is committed to providing breakthrough treatment solutions to patients around the world through continuous innovation.
For more information, please visit: www.ribolia.com.
View original content to download multimedia:^ https://www.prnewswire.com/apac/news-releases/ribo-life-science-06938hk-successfully-lists-on-the-main-board-of-the-hong-kong-stock-exchange-302657128.html
SOURCE Ribo Life Sciences
